ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1264

Vascular Age in Rheumatoid Arthritis Patients

Jl Rosales-Alexander1, César Magro Checa1, Juan Salvatierra1, Silvia Montes García1, Jesús Cantero Hinojosa2 and Enrique Raya Álvarez1, 1Rheumatology, University Hospital San Cecilio, Granada, Spain, 2Internal Medicine, University Hospital San Cecilio, Granada, Spain

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Cardiovascular disease and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects II: Clinical Features & Comorbidity/Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: The European League Against Rheumatism (EULAR) recommends cardiovascular risk (CV) assessment using the systematic coronary risk evaluation (SCORE) chart in rheumatoid arthritis (RA) patients. However, the absolute 10 years CV risk is a statistical and epidemiological concept that could be difficult to understand by our patients, resulting in a lack of adherence to treatment.  The Framinghan heart study (FHS) incorporated the concept of vascular age, as the age of the arteries, a concept more easily understood by all patients. Recently, a calibrated vascular age chart (VAC) according to the SCORE scales was published for european people. 

Objectives: To assess vascular age (VA) in RA patients without CV risk factors/ previous ischemic events using the VAC comparing it with healthy controls. To assess the correlation of several clinical and serological variables with VA. 

Methods: We included 101 consecutive RA patients, according to the 1987 ACR classification criteria, without CV risk factors neither previous ischemic events and matched to 98 healthy controls according to sex, age and gender. We recorded demographic data, clinical and laboratory parameters of disease activity like ESR, CRP, tender and swollen joint counts, DAS28, patient global assessment by visual analogue scale, lipid profile and RA characteristics. We assessed VA  using the VAC.  Data was analyzed with the statistical software SPSS 15. Descriptive data were shown as percentages and mean±SD. To analyze data, we use simple lineal regression test with correlation and the multiple lineal regression analysis. The limit of statistical significance was located in the α error of 0,05.

Results: In RA patients, the median chronologic age (CA) was 53,83±8,28 years, VA was 56,67±9,84  and absolute CV risk was 1,43±1,1. Of these patients, 20% fulfilled EULAR criteria for higher CV risk (20% had more than 10 years of disease, 9% had extra articular manifestations, 77% were positive RF and 48% had ACPA). In controls, CA was 53,52±8,37, VA was 55,78±9,82 and absolute CV risk was 1,1±1. After applying lineal regression test, VA was correlated with CA (beta 1.096, p=0.000); however, there were not differences in VA between both groups (beta -0.62, p=0,232). Of interest, after adjusting for confounding factors, VA seem to be correlated with presence anti-citrullinated peptide antibodies (ACPA) p<0,021. 

Conclusion: In our study we did not find differences between VA in RA patients without CV risk factors in comparison to healthy controls, but we found a well correlation between VA and the CA. Presence of ACPA seems to predict higher vascular age.


Disclosure:

J. Rosales-Alexander,
None;

C. Magro Checa,
None;

J. Salvatierra,
None;

S. Montes García,
None;

J. Cantero Hinojosa,
None;

E. Raya Álvarez,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/vascular-age-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology